Printer Friendly

Acquisition balances victory portfolio.

SAN DIEGO -- Victory Pharma, Inc. has completed its acquisition of almost all of the assets of MiddleBrook Pharmaceuticals Inc.

The addition of MiddleBrook's product portfolio expands Victory's offerings to include the anti-infective drugs Moxtag and Keflex as well as the Pulsys drug delivery technology platform.

"This acquisition reflects our strategy of leveraging our existing commercial infrastructure to expand our portfolio of marketed products," Victory president and chief executive officer Matt Heck says.

"The addition of these products balances our portfolio nicely," he says, explaining that Victory's main drug, the antiarthritis medication Naprelan, is used mostly in the spring and summer, while Moxtag sales peak during the flu season.

Heck says Victory's history of marketing anti-infective drugs should drive sales of Moxtag.

The drug, which is the only once-daily formulation of amoxicillin that has received Food and Drug Administration approval, is indicated for the treatment of tonsillitis and/or pharyngitis.

COPYRIGHT 2010 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Branded Drugs; Victory Pharma, Inc. acquired MiddleBrook Pharmaceuticals Inc.
Publication:Chain Drug Review
Article Type:Brief article
Geographic Code:1USA
Date:Aug 30, 2010
Previous Article:Panel says Avandia should stay.
Next Article:Progress made in war on diabetes.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters